Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels
- 31 October 2010
- journal article
- research article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 40 (1), 340-347
- https://doi.org/10.1016/j.nbd.2010.06.008
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Alzheimer's Disease: Another Target for Heparin TherapyThe Scientific World Journal, 2009
- DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 miceNeurobiology of Disease, 2008
- Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer diseaseNeurobiology of Disease, 2006
- Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein PrecursorJournal of Biological Chemistry, 2004
- Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's DiseaseJournal of Neuroscience, 2004
- Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's DiseaseNeuron, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2001
- Co-expression of multiple transgenes in mouse CNS: a comparison of strategiesBiomolecular Engineering, 2001
- Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein.Proceedings of the National Academy of Sciences of the United States of America, 1996